What Are the Three Obesity Classes and Their BMI Cutoffs?

Obesity classes are a three-tier grading system based on body mass index (BMI) that doctors and researchers use to sort the broad category of “obesity” into increasingly severe levels. Class I covers a BMI of 30.0 to 34.9, Class II spans 35.0 to 39.9, and Class III starts at 40.0 and above. The classes matter because health risks, treatment options, and medical costs all escalate as you move up the scale, though not always in the neat, linear way the numbering implies. The real picture is messier, shaped by where your fat sits, how your metabolism behaves, and factors BMI was never designed to capture.

How the Three Classes Break Down

BMI is calculated from weight and height, and while the formula is the same for everyone, the thresholds that define each obesity class were set by the World Health Organization and adopted by most national health agencies. Normal weight falls between 18.5 and 24.9, overweight is 25.0 to 29.9, and obesity begins at 30.0. From there:

Class I: BMI 30.0–34.9. Sometimes called “moderate obesity,” this is the most common class and the one where individual variation is widest. Many people in this range have few or no metabolic complications.
Class II: BMI 35.0–39.9. Often termed “severe obesity.” Risk of conditions like type 2 diabetes and sleep apnea climbs, and this is the threshold where bariatric surgery starts becoming a clinical conversation, especially when complications are present.
Class III: BMI 40.0 and above. Previously called “morbid obesity,” though that label is falling out of favor. At this level, the association with serious health conditions becomes substantially stronger.

Some clinicians and researchers now recognize additional tiers beyond Class III. A BMI of 50 or above is sometimes called “super-obesity,” and a BMI above 60 is termed “super-super obesity.” Patients at these extremes face elevated surgical and anesthetic risks, and bariatric surgery databases consistently show higher 30-day complication rates and mortality in the super-obese group compared with lower BMI classes.¹ Anesthesiology guidelines flag super-super obesity as a category requiring distinct perioperative planning.²

Health Risks Across the Spectrum

The jump in risk from one class to the next is real, but it is not uniform across all conditions. A large study tracking new diagnoses across all three classes found that Class III obesity was most powerfully linked to obstructive sleep apnea (roughly 11 times the risk compared with normal weight), type 2 diabetes (about 8 times), and fatty liver disease (nearly 7 times). The associations with asthma, osteoarthritis, and cardiovascular disease were elevated too, but more modestly, in the range of about twice the risk.³ In other words, obesity classes do not raise all risks equally. Some conditions respond steeply to increasing BMI, while others plateau or rise gently.

A pooled analysis of 20 large studies estimated that people with Class III obesity lost between roughly 6.5 and nearly 14 years of life compared with normal-weight individuals, depending on where in the BMI 40-to-60 range they fell. Heart disease accounted for the largest share of the excess deaths, followed by cancer and diabetes.⁴ That gradient within Class III itself underscores why some researchers argue for splitting it into finer subcategories.

Even among people classified as having metabolically unhealthy obesity, the class distinction matters. One study using Class I as the reference found that Class III carried about a 48% higher risk of cardiovascular disease, while Class II’s increase was smaller and not statistically reliable on its own.⁵

Where Fat Sits Matters More Than You Would Think

BMI measures total body mass relative to height, but two people with identical BMIs can carry their fat in very different places, and that distinction has outsized consequences. Visceral fat, the kind packed around organs in the abdomen, is consistently more harmful than subcutaneous fat, which sits under the skin and around the hips and thighs. Data from the Framingham Heart Study showed that visceral fat correlated more strongly with metabolic risk factors like blood sugar and blood lipids, even after accounting for BMI and waist circumference.⁶

Research on people already classified as obese found that visceral fat predicted an adverse pattern of cholesterol levels, insulin resistance, and arterial plaque, while subcutaneous fat showed a more benign profile with only modest links to inflammation. The authors described these as “distinct obesity sub-phenotypes,” meaning two people in the same obesity class can face genuinely different levels of cardiovascular and metabolic risk depending on their fat distribution.⁷ The ratio of visceral to subcutaneous fat appears to be a more telling metric than either depot alone.⁸

Metabolically Healthy Obesity and Its Limits

A concept that complicates the neat class structure is “metabolically healthy obesity” (MHO), applied to people who meet BMI criteria for obesity but have normal blood sugar, blood pressure, and lipid levels. The idea is appealing: maybe some people carry extra weight without the metabolic fallout. And there is a biological basis for it. People with MHO tend to have less visceral and liver fat, better insulin sensitivity, and greater cardiorespiratory fitness than metabolically unhealthy people at the same BMI.⁹

But long-term data complicate the optimism. A study of over 3.5 million people found that those classified as metabolically healthy and obese still had about a 49% higher risk of coronary heart disease and nearly double the risk of heart failure compared with metabolically healthy normal-weight individuals.¹⁰ A 20-year cohort study similarly found a 39% higher cardiovascular disease risk in the MHO group.¹¹ MHO also appears to be unstable over time; many people who qualify at one point eventually develop metabolic complications, making it look more like a transitional state than a permanent phenotype.

The practical takeaway: a person in Class I or II obesity with pristine blood work is in a better position than someone at the same BMI with diabetes and high blood pressure, but they are not at the same risk as someone at normal weight with the same clean labs. Obesity class and metabolic status are both worth knowing, and neither fully captures the picture alone.

Why Standard Cutoffs Do Not Fit Everyone

The BMI thresholds used to define each obesity class were developed primarily using data from White European populations, and they do not translate cleanly across ethnic groups. Asian populations tend to develop type 2 diabetes and cardiovascular disease at lower BMIs because they accumulate proportionally more visceral fat at any given weight. A WHO expert consultation concluded that a substantial proportion of Asian people face high cardiometabolic risk at BMIs below the standard overweight threshold of 25.¹² Several organizations now recommend lower obesity cutoffs for Asian populations, starting at a BMI of 25 or 27.5 instead of 30.¹³

A large population study in England quantified the gap. To match the type 2 diabetes incidence seen in White populations at a BMI of 30, the equivalent BMI was about 24 in South Asian populations, about 27 in Chinese and Arab populations, and about 28 in Black populations.¹⁴ That means a South Asian person at BMI 25 may already be carrying a Class I-equivalent metabolic risk while technically being classified as merely “overweight” on the standard scale. If you are reading this and wondering why your doctor flagged your weight at a BMI of 26 or 27, your ethnic background may be the reason.

How Children Are Classified Differently

Kids and teenagers do not use the same fixed BMI numbers as adults, because their body composition changes as they grow. Instead, pediatric obesity is defined using percentiles relative to age- and sex-matched growth charts. Obesity in children is generally a BMI at or above the 95th percentile. Severe obesity, roughly analogous to the adult Class III concept, is typically defined as a BMI at or above 120% of the 95th percentile.¹⁵ A separate classification once used the 99th percentile as the severe obesity line, but research comparing the two approaches found that the 120%-of-the-95th-percentile marker did a better job identifying children with elevated cardiometabolic risk, especially those under 10.¹⁶

Childhood obesity classes matter partly because of trajectory. A simulation study using nationally representative data found that childhood severe obesity substantially increased the probability of adult obesity, linking the pediatric 120%-of-95th-percentile threshold to adult BMIs of 35 and above.¹⁷ Catching severe obesity early in childhood is one of the few contexts where classification alone can meaningfully change the clinical path.

Staging Systems That Go Beyond BMI

Growing dissatisfaction with BMI as a one-dimensional number has led to clinical staging systems that try to capture the actual health burden of obesity. The most studied is the Edmonton Obesity Staging System (EOSS), which classifies patients on a five-stage scale (0 through 4) based not on weight but on the presence and severity of obesity-related comorbidities and functional impairment. A study of real-world clinical data found that BMI class and EOSS stage barely overlapped: similar proportions of patients from each BMI class fell into each EOSS stage, and BMI alone accounted for just over 1% of the variation in staging.¹⁸ In plainer terms, knowing someone’s BMI class told you almost nothing about how sick they actually were.

When applied to hospitalized patients, higher EOSS stages predicted both higher readmission rates and higher mortality in a stepwise fashion, which BMI class alone did not do as cleanly.¹⁹ The argument for staging is not that BMI is useless but that it captures only one dimension. Two people both in Class II obesity, one with well-controlled blood pressure and an active lifestyle, the other with diabetes, sleep apnea, and limited mobility, are in fundamentally different clinical situations. Staging systems attempt to make that distinction formal.

The Obesity Paradox

One of the stranger findings in the obesity literature is that in certain chronic diseases, being overweight or mildly obese is associated with better survival than being normal weight. This “obesity paradox” has been documented in heart failure, advanced kidney disease, chronic lung disease, and some cancers.²⁰ In heart failure specifically, unadjusted survival data show an overall survival advantage for people with higher body weight.²¹ The paradox appears strongest in overweight and Class I obesity and weakens or disappears at higher classes.²² Among dialysis patients, the survival benefit of higher BMI has been fairly consistent across racial groups, though the data are mixed for some dialysis types.²³

This does not mean that obesity is protective in some general sense. The paradox is specific to people who already have serious chronic illnesses, and much of it may reflect the fact that unintentional weight loss in those diseases is a sign of wasting and decline. Having metabolic reserves can buffer against the catabolic stress of advanced illness. The class distinction is important here: the protective signal fades as you move into Class II and III, where the metabolic burden of the obesity itself starts to overwhelm any reserve benefit.

Sarcopenic Obesity Adds Another Layer

BMI-based obesity classes assume that excess weight is mostly fat, but in older adults especially, the picture gets complicated by muscle loss. Sarcopenic obesity describes a person who has both excess fat and low muscle mass or muscle function. It is increasingly common in people over 65 and represents a distinct geriatric syndrome with compounding risks from both conditions.²⁴ European clinical societies now recommend a two-stage diagnostic approach: first screen for low muscle function, then confirm with body composition measurements that show both excess fat and low muscle mass. Confirmed cases are staged into Stage I (no clinical complications) or Stage II (with complications linked to the altered body composition).²⁵

The mortality implications are steep. A study of older adults found that those with sarcopenic obesity and two altered body-composition components had nearly triple the risk of death compared with those without the condition.²⁶ A person with Class I obesity and good muscle mass is in a very different position from someone at the same BMI whose weight includes proportionally less muscle and more fat. This is another way the class system, which sees only a number, can miss what matters.

Treatment Approaches Across Classes

Treatment intensity generally tracks with obesity class, though the boundaries are not rigid. Lifestyle interventions, combining diet, physical activity, and behavioral strategies, are first-line across all classes. A systematic review of programs designed for people with Class II and III obesity found that the most effective ones ran for about a year with frequent contact, either weekly in community settings or through intensive clinic stays. The best-performing programs achieved clinically meaningful weight loss in a majority of participants, though the review noted that even successful weight loss did not always translate into improvements in blood pressure, cholesterol, or blood sugar.²⁷

A question that comes up often is whether lifestyle changes work as well for people at higher BMIs. The evidence is mixed. Some studies found that people with higher starting BMIs lost more absolute weight, while others found no difference between classes. Improvements in cholesterol, blood pressure, and blood sugar were generally similar across Class II and III at one year.²⁸

GLP-1 receptor agonist medications like semaglutide have shifted the landscape. These drugs can produce average weight loss of roughly 15% to 25% of body weight over about a year.²⁹ Real-world data suggest that patients with Class III obesity lose similar amounts of absolute weight as those in lower classes on semaglutide, though their percentage weight loss tends to be slightly lower because they start from a higher baseline.³⁰

Bariatric surgery remains the most durable option for severe obesity. A retrospective comparison found that patients with what some researchers now call “Class 4 obesity” (BMI 50 and above) achieved slightly higher total weight loss after surgery than those in Classes II and III. Rates of diabetes and hypertension remission were similar between groups. However, mortality was significantly higher in the Class 4 group.³¹

Why Weight Regain Is So Common

Regardless of obesity class or treatment method, the biology of weight maintenance works against sustained loss. After losing weight, the body mounts a coordinated defense: metabolic rate drops below what would be expected for the new body size, appetite hormones shift to increase hunger, and the hormone leptin, which signals energy reserves to the brain, falls disproportionately. This phenomenon, called adaptive thermogenesis, creates strong pressure to regain lost weight. Estimates suggest that over 80% of people who lose weight eventually return to their previous levels of body fat.³² These responses operate in both lean and obese people, meaning they are not a flaw of obesity but a deeply embedded feature of human energy regulation. Understanding this helps explain why obesity is classified as a chronic disease requiring ongoing management rather than a problem you solve once.

The Economic Cost Gradient

Healthcare spending rises sharply with obesity class. Across the United States, adults with obesity incurred roughly double the annual medical costs of normal-weight adults, but this average obscures a steep gradient: Class I costs were about 68% higher, while Class III costs were about 234% higher.³³ A broader systematic review reported per-person annual costs ranging from 1.1 times normal weight for Class I to 3.3 times for Class III.³⁴

The gap also widens over time. An eight-year longitudinal study found that the cost difference between Class III and Class I grew from about 27% in the first year to about 41% by year eight, with outpatient visits accounting for about half of total spending across all classes.³⁵ This accelerating divergence reflects the accumulation of obesity-related complications over time, especially in higher classes. It is one of the reasons health systems and insurers are increasingly willing to cover intensive treatments, including medications and surgery, at earlier stages.

Quality of Life and Weight Stigma

The effects of obesity class extend well beyond metabolic risk. A cross-sectional analysis of a large Brazilian national survey found that increasing obesity severity was associated with worse self-rated health, more vitality-related problems like fatigue, and higher rates of perceived discrimination or psychological violence.³⁶ Internalized weight stigma, where a person absorbs negative societal attitudes about weight and applies them to themselves, predicted poorer quality of life across emotional, social, and sexual domains regardless of whether someone had obesity or was simply overweight.³⁷

Weight stigma from healthcare providers is a documented barrier to care. People in higher obesity classes report avoiding medical visits, delaying preventive screenings, and distrusting clinical recommendations. The class label itself can become a source of shame if communicated clumsily. This is one reason many obesity medicine specialists now prefer to lead conversations with complication-based staging rather than BMI numbers alone: a discussion framed around sleep quality, joint pain, or blood sugar control tends to be more productive than one framed around a category number.

1
PubMed. Five Years of MBSAQIP Data: Characteristics, Outcomes, and Trends for Patients with Super-obesity ↩︎
2
PubMed Central. The patient with obesity and super-super obesity: Perioperative anesthetic considerations ↩︎
3
PubMed. Associations between Class I, II, or III Obesity and Health Outcomes ↩︎
4
PubMed Central. Association between class III obesity (BMI of 40-59 kg/m2) and mortality: a pooled analysis of 20 prospective studies ↩︎
5
PubMed. Relationship between obesity severity, metabolic status and cardiovascular disease in obese adults ↩︎
6
PubMed. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study ↩︎
7
PubMed Central. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults ↩︎
8
PubMed Central. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk ↩︎
9
PubMed Central. Metabolically Healthy Obesity ↩︎
10
PubMed. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women ↩︎
11
International Journal of Obesity. Metabolically healthy obesity is independently associated with 20-year incidence of cardiovascular disease: findings from the ATTICA cohort study (2002–2022) ↩︎
12
PubMed. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies ↩︎
13
PubMed Central. Obesity among Asian American people in the United States: A review ↩︎
14
PubMed Central. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study ↩︎
15
PubMed Central. Severe obesity in children: prevalence, persistence and relation to hypertension ↩︎
16
PLoS ONE. Severe Obesity and Cardiometabolic Risk in Children: Comparison from Two International Classification Systems ↩︎
17
PubMed Central. Simulation of Growth Trajectories of Childhood Obesity into Adulthood ↩︎
18
PubMed Central. Using the Edmonton Obesity Staging System in the real world: a feasibility study based on cross-sectional data ↩︎
19
Revista Clínica Española (English Edition). Prognostic value of the Edmonton Obesity Staging System among people hospitalized with obesity ↩︎
20
PubMed Central. The Obesity Paradox in Kidney Disease: How to Reconcile it with Obesity Management ↩︎
21
PubMed. The Heart Failure Overweight/Obesity Survival Paradox: The Missing Sex Link ↩︎
22
PubMed. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases ↩︎
23
PubMed Central. Obesity paradox in end-stage kidney disease patients ↩︎
24
PubMed Central. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies ↩︎
25
PubMed Central. Consensus Statement Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement ↩︎
26
JAMA Network Open. Sarcopenia and Sarcopenic Obesity and Mortality Among Older People ↩︎
27
PubMed Central. Behavioral lifestyle interventions for moderate and severe obesity: A systematic review ↩︎
28
PLoS ONE. Effects of Lifestyle Interventions That Include a Physical Activity Component in Class II and III Obese Individuals: A Systematic Review and Meta-Analysis ↩︎
29
PubMed Central. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss ↩︎
30
JAMA Network Open. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity ↩︎
31
PubMed. Comparative Outcomes of Bariatric Surgery in Individuals with Class 2-3 and Class 4 Obesity: A Retrospective Cohort Study ↩︎
32
PubMed Central. Adaptive thermogenesis in humans ↩︎
33
PubMed Central. Direct medical costs of obesity in the United States and the most populous states ↩︎
34
PubMed Central. Costs of obesity, obesity-related complications, and weight loss in the United States: A systematic literature review ↩︎
35
PubMed. Eight-year trends in obesity-related complications and health care cost progression in a US population with obesity: A retrospective cohort study ↩︎
36
Scientific Reports. Association between quality-of-life-related indicators and obesity severity categories (Classes I–III): a cross-sectional analysis of the 2019 Brazilian National Health Survey ↩︎
37
PubMed Central. Internalized weight stigma and obesity-related quality of life in adults with obesity or overweight: a cross-sectional study across clinical and community settings ↩︎